

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

| Term | Documents |
|--|-----------|
| (1 AND 3).USPT,PGPB,JPAB,EPAB,DWPI,TDBD. | 26 |
| (L3 AND L1).USPT,PGPB,JPAB,EPAB,DWPI,TDBD. | 26 |

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Thursday, February 06, 2003
[Printable Copy](#)
[Create Case](#)

| <u>Set Name</u> side by side | <u>Query</u> | <u>Hit Count</u> | <u>Set Name</u> result set |
|---|--------------------------------------|------------------|-------------------------------|
| <i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i> | | | |
| <u>L4</u> | L3 and l1 | 26 | <u>L4</u> |
| <u>L3</u> | intravenous or inject\$6 or parental | 987506 | <u>L3</u> |
| <u>L2</u> | arabinogalactan | 746 | <u>L2</u> |
| <u>L1</u> | astragalus membranaceus | 282 | <u>L1</u> |

END OF SEARCH HISTORY

WEST**End of Result Set**

Generate Collection

Print

L4: Entry 26 of 26

File: DWPI

Dec 19, 1990

DERWENT-ACC-NO: 1991-267582

DERWENT-WEEK: 199137

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Injection compsn. for anal-fistula - comprises Gleditia sinensis, Astragalus membranaceus, Coptis chinensis and centipede NoAbstract

INVENTOR: DENG, K

PATENT-ASSIGNEE:

ASSIGNEE

CODE

DENG K

DENG I

PRIORITY-DATA: 1990CN-0105504 (July 20, 1990)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|--------------|-------------------|----------|-------|------------|
| CN 1047806 A | December 19, 1990 | | 000 | |
| CN 1025590 C | August 10, 1994 | | 000 | A61K035/78 |

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|-------------|---------------|----------------|------------|
| CN 1047806A | July 20, 1990 | 1990CN-0105504 | |
| CN 1025590C | July 20, 1990 | 1990CN-0105504 | |

INT-CL (IPC): A61K 35/78

ABSTRACTED-PUB-NO:

EQUIVALENT-ABSTRACTS:

TITLE-TERMS: INJECTION COMPOSITION ANUS FISTULA COMPRISE SINENSIS ASTRAGALUS COPTIS CHINENSIS NOABSTRACT

DERWENT-CLASS: A96 B04

CPI-CODES: B04-A07F2; B04-B04M;

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1991-115990

WEST

Generate Collection

Print

L4: Entry 25 of 26

File: DWPI

Aug 14, 1991

DERWENT-ACC-NO: 1991-239859

DERWENT-WEEK: 199133

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New polysaccharide(s) extracted from Astragalus membranaceus - are immuno-modulators, and may be used to treat or prevent bacterial and viral infections, or in chemotherapy

INVENTOR: BOMBARDELL, E; POZZI, R

PATENT-ASSIGNEE:

ASSIGNEE

CODE

INDENA SPA

INDEN

PRIORITY-DATA: 1990IT-0019325 (February 9, 1990)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---------------|-------------------|----------|-------|------------|
| EP 441278 A | August 14, 1991 | | 000 | |
| CA 2035948 A | August 10, 1991 | | 000 | |
| IT 1238685 B | September 1, 1993 | | 000 | A61K000/00 |
| JP 05039305 A | February 19, 1993 | | 004 | C08B037/00 |

DESIGNATED-STATES: AT BE CH DE ES FR GB GR IT LI LU NL SE

CITED-DOCUMENTS: 2.Jnl.Ref; EP 30444 ; US 4843067

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|--------------|------------------|----------------|------------|
| EP 441278A | February 4, 1991 | 1991EP-0101424 | |
| IT 1238685B | February 9, 1990 | 1990IT-0019325 | |
| JP 05039305A | February 7, 1991 | 1991JP-0102196 | |

INT-CL (IPC): A61K 31/71; A61K 31/715; A61K 35/78; C08B 37/00

ABSTRACTED-PUB-NO: EP 441278A

BASIC-ABSTRACT:

Polysaccharides of mol. wt. 12000-500000 (125000-250000, and more specifically 456000 and 213000) Daltons are claimed. They are extracted from the roots of plants of the genus Astragalus (especially Astragalus membranaceus (I)).

More specifically, they are prep'd. by extracting finely ground roots of (I) with aliphatic alcohols, then alcohol contg. 20-50% water. The extracts are then digested with aq. alkali at - to + 45 deg.C for 3-30 hrs. The polysaccharide fractions are purified by one or more of 3 claimed steps-e.g. pptn. of proteins by denaturation in acids or extn. with boiling water and concn. under reduced pressure. They are then ptd., dialysed, subjected to HPLC or lyophilised as appropriate.

USE/ADVANTAGE - The polysaccharides are useful in treatment and prevention of bacterial and viral injections (including the AIDS virus) and as immunomodulators. They are helpful in radiation antineoplastic and chemotherapy. Dose is oral or by injection at 10-100 mg/kg.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: NEW POLYSACCHARIDE EXTRACT ASTRAGALUS IMMUNO MODULATE TREAT PREVENT BACTERIA VIRUS INFECT CHEMOTHERAPEUTIC

DERWENT-CLASS: B04

CPI-CODES: B04-C02D; B12-A01; B12-A06; B12-C09; B12-D02B;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M710 M903 P210 P220 P433 P434 P861 V400 V406

V735

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1991-104233

WEST

Generate Collection

Print

L4: Entry 18 of 26

File: EPAB

Aug 14, 1991

PUB-NO: EP000441278A1

DOCUMENT-IDENTIFIER: EP 441278 A1

TITLE: Polysaccharides with immunomodulating properties from astragalus membranaceus and pharmaceutical compositions containing them.

PUBN-DATE: August 14, 1991

INVENTOR-INFORMATION:

NAME

COUNTRY

BOMBARDELLI, EZIO

IT

POZZI, ROBERTO

IT

ASSIGNEE-INFORMATION:

NAME

COUNTRY

INDENA SPA

IT

APPL-NO: EP91101424

APPL-DATE: February 4, 1991

PRIORITY-DATA: IT01932590A (February 9, 1990)

INT-CL (IPC): A61K 31/715; A61K 35/78; C08B 37/00

EUR-CL (EPC): C08B037/00

ABSTRACT:

CHG DATE=19990617 STATUS=O> New glucanes (Astraglucones) and their mixture with other polysaccharides extracted from the roots and rhizomes of Astragalus membranaceus and other species, endowed with immunomodulating properties, are disclosed. These new products find their application as an aid in radiation antineoplastic therapy, in chemotherapy and in the treatment and prevention of bacterial and viral infections. Said products are active by oral route and after injection and are suitable for incorporation into the most common pharmaceutical formulations.